Drug intelligence / Profile preview

GB3010

Development stage: Phase 1
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GB3010 is a T Cell Receptor T Cell (TCR-T) therapy being investigated for the treatment of advanced pancreatic cancer. This therapy involves engineered T cells that express specific T cell receptors designed to target cancer cells. The treatment is currently being evaluated for its safety, tolerability, efficacy, and pharmacokinetics in clinical trials.

Other names: TCRT cell injectionT Cell Receptor T Cell Therapy

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on GB3010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB3010.

Explore the full profile